Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Total Liabilities: 2020-2025

Historic Total Liabilities for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $50.1 million.

  • Tango Therapeutics' Total Liabilities fell 59.35% to $50.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year decrease of 59.35%. This contributed to the annual value of $117.0 million for FY2024, which is 21.73% down from last year.
  • Tango Therapeutics' Total Liabilities amounted to $50.1 million in Q3 2025, which was down 51.32% from $102.9 million recorded in Q2 2025.
  • Tango Therapeutics' Total Liabilities' 5-year high stood at $191.1 million during Q3 2022, with a 5-year trough of $6.1 million in Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $133.8 million (2024), whereas its average is $129.1 million.
  • Per our database at Business Quant, Tango Therapeutics' Total Liabilities surged by 25,342.41% in 2021 and then tumbled by 59.35% in 2025.
  • Over the past 5 years, Tango Therapeutics' Total Liabilities (Quarterly) stood at $155.4 million in 2021, then grew by 20.32% to $187.0 million in 2022, then declined by 20.07% to $149.5 million in 2023, then dropped by 21.73% to $117.0 million in 2024, then crashed by 59.35% to $50.1 million in 2025.
  • Its Total Liabilities was $50.1 million in Q3 2025, compared to $102.9 million in Q2 2025 and $107.5 million in Q1 2025.